Mucopolysaccharidoses

Slide 1 · Mucopolysaccharidoses

Inherited glycosaminoglycan storage disorders:

from lysosomal dysfunction to skeletal disease

Mechanisms • morphology • clinicopathologic correlations

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Explain glycosaminoglycan storage from a deficient lysosomal catabolic step.

Relate chondrocyte injury and matrix abnormalities to skeletal deformities.

Recognize the principal histologic, systemic, and syndrome-specific findings.

Distinguish Hurler from Hunter syndrome using enzyme, inheritance, and corneal findings.

Slide 3 · The central clinicopathologic problem

A lysosomal enzymatic defect prevents normal degradation of glycosaminoglycans.

The same substrate burden affects connective tissues, viscera, vasculature, and sometimes neurons.

Bone deformity is one component of a multisystem storage disorder.

Key concept: The skeleton and internal organs share one biochemical defect.

Slide 4 · How the biochemical defect becomes a phenotype

Enzyme

Deficiency

Lysosomal GAG

Accumulation

Cellular and matrix

Dysfunction

Organ-specific

Disease

Accumulating substrate has different consequences in cartilage, viscera, heart, and CNS.

Slide 5 · A lysosomal storage disease—not a primary collagenopathy

Mucopolysaccharidoses are inherited defects of lysosomal substrate degradation.

The stored substrate is glycosaminoglycan, not type I collagen.

Skeletal pathology arises largely from altered cartilage development, growth, and joint structure.

Slide 6 · Glycosaminoglycans are major matrix constituents

Why the substrate is important in cartilage and connective tissue

Long, complex carbohydrate chains.

Linked with core proteins to form proteoglycans.

Abundant in extracellular matrix, connective tissue, and joint fluid.

Core protein

Glycosaminoglycan chains

Conceptual proteoglycan schematic

Slide 7 · The four glycosaminoglycans emphasized in MPS

Accumulating glycosaminoglycan

Biologic context

Dermatan sulfate

Proteoglycan-associated connective tissue constituent

Heparan sulfate

Proteoglycan-associated glycosaminoglycan

Keratan sulfate

Contributes to connective tissue and cartilage matrix

Chondroitin sulfate

Component of proteoglycan-rich extracellular matrix

Source lists four storage substrates; Distribution and severity vary across disease types.

Slide 8 · Why proteoglycan turnover requires enzymes

Glycosaminoglycan chains cannot be cleared in a single nonspecific reaction.

A sequence of lysosomal enzymes normally removes successive sugar residues.

Loss of one required activity leaves incompletely degraded chains.

Slide 9 · Normal lysosomal glycosaminoglycan clearance

Matrix

Proteoglycan turnover

Lysosomal

Processing

Sequential terminal

Sugar cleavage

Degradation

Products recycled

The degradative pathway depends on multiple functioning lysosomal hydrolases.

Slide 10 · Deficient acid hydrolase: The biochemical bottleneck

Many implicated enzymes are lysosomal acid hydrolases.

One missing or malfunctioning step interrupts GAG catabolism.

Substrate remains within the lysosomal compartment.

Extracellular matrix

Proteoglycans

Cellular uptake and

Lysosomal turnover

Incomplete substrate

Degradation

Slide 11 · Normal clearance versus the storage state

Functioning degradation

Enzymatic cleavage proceeds sequentially.

Products can be processed and recycled.

Lysosomal substrate does not progressively accumulate.

Enzyme deficiency

A required cleavage step is blocked.

Residual GAG fragments persist.

Lysosomes enlarge with stored material.

Mechanistic comparison—original conceptual schematic.

Slide 12 · Primary lysosomal storage is the initiating lesion

Inherited enzyme deficiency is the primary molecular defect.

Unmetabolized glycosaminoglycans accumulate within lysosomes.

Cell enlargement and malfunction follow accumulation across susceptible tissues.

Slide 13 · Substrate localization predicts the organs at risk

MPS affects cells that encounter or degrade GAG-rich material.

Mesenchymal cells have major roles in extracellular matrix turnover.

Systemic substrate distribution contributes to multisystem pathology.

Cartilage and joints

Vascular / cardiac tissue

Liver and spleen

Brain in some variants

Slide 14 · Why chondrocytes are a pivotal target

Cartilage ECM

Turnover

Defective GAG

Clearance

Chondrocyte

Lysosomal storage

Chondrocyte

Injury

The chapter links storage in chondrocytes to apoptosis and cartilage malfunction.

Slide 15 · Chondrocyte apoptosis drives a skeletal component

Glycosaminoglycans accumulate within affected chondrocytes.

The accumulated material is associated with chondrocyte apoptosis.

Loss of viable cells compromises cartilage integrity and normal skeletal growth.

Slide 16 · Extracellular storage adds structural matrix injury

Abnormal glycosaminoglycans also accumulate outside cells.

The extracellular burden produces structural defects in articular cartilage.

Intracellular toxicity and matrix disruption act together.

Intracellular storage

Chondrocyte injury

Extracellular GAG excess

Abnormal cartilage architecture

Slide 17 · Two convergent routes to cartilage pathology

Lysosomal GAG

Storage

Chondrocyte injury

And apoptosis

Abnormal cartilage

Architecture

Skeletal

Manifestations

Extracellular substrate accumulation additionally disrupts articular cartilage.

Slide 18 · The skeletal sites named by Robbins

Four cartilage-dependent structures explain the skeletal phenotype

Cartilage anlage: The early skeletal template.

Growth plates: Normal longitudinal growth.

Costal cartilages: Chest-wall configuration.

Articular surfaces: Joint structure.

Cartilage anlage

Early skeletal template

Growth plate

Longitudinal bone growth

Costal cartilage

Chest wall architecture

Articular surface

Joint integrity

Slide 19 · Cartilage anlage and malformed bones

The cartilage model guides development of many skeletal elements.

MPS-related structural abnormalities affect that template.

Malformed bones can therefore arise during skeletal development.

Slide 20 · Growth-plate injury and short stature

Endochondral bone growth depends on growth-plate cartilage.

Stored GAGs disrupt the cellular and matrix environment.

Impaired longitudinal growth helps explain short stature in MPS.

Slide 21 · Costal cartilage and chest-wall abnormalities

Ribs and sternum depend on costal cartilage for normal architecture.

Disease affects this cartilage compartment.

Chest-wall abnormalities are among the frequent skeletal manifestations.

Slide 22 · Articular cartilage defects and joint disease

Extracellular GAG accumulation compromises cartilage structure.

Articular surfaces participate in the skeletal phenotype.

Joint stiffness is a typical clinical manifestation.

Slide 23 · From cartilage dysfunction to recognizable skeletal disease

Storage in

Chondrocytes

Apoptosis + abnormal

Extracellular matrix

Growth and articular

Cartilage dysfunction

Short stature +

Malformed bones

The combined cellular and extracellular mechanism explains the skeletal phenotype.

Slide 24 · Intracellular and extracellular contributions

Inside the chondrocyte

Accumulated GAGs in lysosomes.

Chondrocyte injury and apoptosis.

Reduced maintenance of cartilage.

Within the matrix

Excess extracellular GAGs.

Structural defects of articular cartilage.

Altered mechanical tissue integrity.

Two linked, not mutually exclusive, pathways.

Slide 25 · MPS constitutes a genetically heterogeneous group

Different enzyme defects produce related storage phenotypes.

11 clinical variants.

Phenotypes can overlap because many variants affect GAG metabolism.

Slide 26 · One enzyme deficiency can produce variable severity

Different mutations can alter residual enzyme activity to different degrees.

Subgroups can arise within a nominal MPS type.

Clinical severity may therefore differ even when the affected enzyme is the same.

Slide 27 · Most MPS variants versus Hunter syndrome

Most MPS disorders

Autosomal recessive inheritance.

Disease typically requires pathogenic alleles affecting both copies of the relevant gene.

Both sexes can be affected.

Hunter syndrome (MPS II)

X-linked recessive inheritance.

The important inheritance exception in this group.

Sex-linked pedigree pattern guides suspicion.

Inheritance informs genetic counseling and diagnostic evaluation.

Slide 28 · Autosomal recessive inheritance predominates

All MPS types except Hunter are described as autosomal recessive.

Carrier parents may be clinically unaffected.

A positive family history is helpful but not essential for recognition.

Autosomal recessive

MPS (most types)

Inherited pathogenic alleles

From both parents

Slide 29 · Hunter syndrome is the X-linked exception

MPS II is inherited as an X-linked recessive trait.

This mode differs fundamentally from most other MPS syndromes.

The inheritance pattern helps separate related clinical phenotypes.

MPS II (Hunter)

X-linked inheritance

Distinct exception to the usual

Autosomal-recessive pattern

Slide 30 · Clinical variability makes morphology informative

No single symptom identifies every MPS subtype.

Systemic storage can affect multiple organs to differing extents.

Enzyme phenotype, inheritance, ocular findings, and course improve discrimination.

Slide 31 · MPS generally follows a progressive course

Storage is driven by continuing substrate production and impaired clearance.

Clinical signs become more evident as the disease advances.

The rate and intensity of progression vary between specific syndromes.

Slide 32 · A characteristic clinical constellation

Coarse facial features occur across the group.

Joint stiffness and skeletal deformities are common.

Corneal clouding and intellectual impairment occur in some forms.

Coarse facial features

Skeletal deformity

Joint stiffness

Corneal / neurologic findings

Slide 33 · Coarse facial features reflect multisystem storage

A coarse facial appearance is characteristic of the MPS group.

It is interpreted alongside the skeletal and visceral manifestations.

Its presence is a clinical clue, not a specific enzyme diagnosis.

Slide 34 · Corneal clouding provides a useful clinical discriminator

Corneal clouding is part of the general MPS phenotype.

It is highlighted in severe Hurler syndrome.

Hunter syndrome classically lacks corneal clouding in the Robbins comparison.

Slide 35 · Joint stiffness should prompt systemic assessment

Joint stiffness is included among the recurring manifestations.

The cartilage defect links joint findings to the metabolic storage process.

A skeletal presentation alone may miss cardiac or visceral disease.

Slide 36 · Intellectual impairment reflects CNS involvement in some forms

Some MPS syndromes cause storage-related neuronal abnormalities.

Intellectual disability appears in the general clinical description.

Neurologic severity is not uniform across all variants.

Slide 37 · Hepatosplenomegaly reflects visceral storage

Liver and spleen are common sites of glycosaminoglycan accumulation.

Increased cellular substrate burden can produce organ enlargement.

Hepatosplenomegaly is prominent in the Hurler clinical description.

Slide 38 · Skeletal and visceral signs should be integrated

Short stature and malformed bones identify the skeletal component.

Coarse facies, hepatosplenomegaly, and joint findings suggest systemic storage.

Cardiac and neurologic evaluation is important to characterize disease extent.

Slide 39 · The heart and arteries are major targets

Valvular lesions are described in the MPS group.

Arterial subendothelial deposits, especially coronary, may develop.

Severe involvement produces clinically important cardiovascular complications.

GAG deposition

In vessel intima

Coronary luminal compromise

Myocardial ischemia

Slide 40 · Cardiac valves: A storage-related lesion

Glycosaminoglycan storage affects cardiac and vascular connective tissues.

Valvular deposits cause structural valvular lesions.

Cardiac abnormalities are significant contributors to disease morbidity.

Slide 41 · Coronary subendothelial storage and ischemia

Subendothelial

GAG deposits

Coronary arterial

Lesions

Impaired myocardial

Perfusion

Ischemia and

Possible infarction

Myocardial ischemia and cardiac decompensation as important causes of death.

Slide 42 · Cardiovascular disease can dominate late outcomes

Coronary lesions occur particularly in more protracted syndromes.

Myocardial ischemia and infarction may follow subendothelial disease.

Cardiac decompensation can be fatal.

Slide 43 · MPS is a systemic histopathologic storage process

GAG storage occurs in mononuclear phagocytes, fibroblasts, endothelium, and intimal smooth muscle.

The burden affects multiple tissue compartments rather than a single lineage.

Affected cells become enlarged by lysosomal distension.

Mononuclear phagocytes

Endothelial cells

Intimal smooth muscle

Fibroblasts

Slide 44 · Balloon cells reflect enlarged storage lysosomes

Microscopically, affected cells may appear distended.

Cytoplasmic clearing creates the balloon-cell appearance.

This appearance is linked to storage, not a unique cell lineage.

Reference

Cell

Stored lysosomes

(balloon cell)

Simplified cellular schematic — not a micrograph

Slide 45 · The vacuolated cytoplasm has an ultrastructural basis

Clear cytoplasm represents numerous minute vacuoles.

Electron microscopy identifies distended lysosomal compartments.

These lysosomes contain the material that failed to undergo normal catabolism.

Slide 46 · Stored material has a biochemical identity

Swollen lysosomes contain finely granular material.

This material as periodic acid–Schiff positive.

Biochemical characterization identifies the substrate as mucopolysaccharide.

Slide 47 · Light microscopy versus electron microscopy

Light microscopic pattern

Enlarged cells with pale or cleared cytoplasm.

Balloon-cell appearance due to intracytoplasmic storage.

PAS-positive storage material is described.

Ultrastructural correlate

Numerous minute lysosomal vacuoles.

Expanded secondary storage compartments.

Neuronal lamellated inclusions in selected syndromes.

Interpret clearing as a lysosomal-storage finding, not an isolated diagnosis.

Slide 48 · Storage is distributed across reticuloendothelial organs

Common affected sites include liver and spleen.

Bone marrow and lymph nodes may contain affected cells.

Distribution helps account for organ enlargement and multisystem manifestations.

Slide 49 · Neuronal involvement changes the clinical phenotype

Some variants also store GAGs within neurons.

Neuronal lysosomes may contain lamellated inclusions.

CNS pathology correlates with cognitive and neurologic involvement.

Slide 50 · MPS I: Deficiency of α-L-iduronidase

Hurler syndrome is a severe form of MPS I.

The deficient lysosomal enzyme is α-L-iduronidase.

Dermatan sulfate and heparan sulfate are specified accumulating substrates Table 5.6.

Slide 51 · Hurler syndrome: Evolution of the severe phenotype

Apparently normal

At birth

Hepatosplenomegaly

In early childhood

Growth, facial and

Skeletal changes

Major cardiovascular

Complications

The source describes hepatosplenomegaly becoming evident by 6–24 months.

Slide 52 · Hurler syndrome: Clinically severe childhood disease

The severe phenotype includes retarded growth and skeletal deformities.

Coarse facial features and corneal clouding support recognition.

Childhood mortality, frequently from cardiovascular disease.

Slide 53 · MPS II: Hunter syndrome

Hunter syndrome results from iduronate 2-sulfatase deficiency.

It has X-linked recessive inheritance.

Compared with Hurler syndrome, absent corneal clouding and a milder course.

Slide 54 · Hurler syndrome and Hunter syndrome compared

Feature

Hurler syndrome (MPS I-H)

Hunter syndrome (MPS II)

Deficient enzyme

α-L-iduronidase

Iduronate 2-sulfatase

Inheritance

Autosomal recessive

X-linked recessive

Corneal clouding

Characteristic

Classically absent

Course in textbook

Severe childhood course

Generally milder than Hurler

The contrast is syndrome-level and does not capture all possible phenotypic variants.

Slide 55 · Why phenotypic overlap does not remove diagnostic distinctions

Coarse facies and skeletal disease may occur in more than one MPS.

Inherited enzyme deficiencies and substrate accumulation are shared mechanisms.

Enzyme identity, inheritance, and ocular findings distinguish MPS I-H and MPS II.

Slide 56 · Urinary glycosaminoglycan excretion is a diagnostic clue

Stored mucopolysaccharides are often excreted in increased amounts in urine.

Urinary GAG testing therefore provides a biochemical diagnostic clue.

Urinary abnormalities do not, by themselves, identify the precise enzyme defect.

Slide 57 · A source-grounded diagnostic reasoning sequence

Recognize multisystem

Clinical pattern

Demonstrate increased

Urinary GAGs

Define the implicated

Enzyme deficiency

Integrate pedigree and

Syndrome phenotype

Clinical suspicion and biochemical specificity answer different questions.

Slide 58 · Diagnostic interpretation requires several layers

Clinical pattern: Skeletal, ocular, visceral, cardiovascular, neurologic features.

Biochemical level: Accumulating glycosaminoglycans.

Molecular level: A deficient lysosomal enzyme and its inherited cause.

Slide 59 · MPS versus other lysosomal storage diseases

Mucopolysaccharidoses

Primary accumulation of glycosaminoglycans.

Cartilage, connective-tissue, and vascular disease.

Coarse facies and skeletal abnormalities.

Other storage diseases

May primarily store glycolipids or glycogen.

Organ distribution follows stored substrate and cell type.

Certain diseases show neurologic or visceral patterns.

Shared lysosomal mechanism; Different accumulated substrates.

Slide 60 · Clinicopathologic application: Case 1

A child appears normal at birth, then develops hepatosplenomegaly, impaired growth, coarse facial features, skeletal deformities, and corneal clouding.

Which MPS syndrome is strongly suggested, and which enzyme is deficient?

Slide 61 · Case 1 interpretation

The constellation strongly suggests the severe MPS I phenotype (Hurler syndrome).

α-L-iduronidase deficiency underlies this syndrome.

A biochemical and genetic workup would establish the subtype rather than the phenotype alone.

Clinical phenotype is suggestive—not a substitute for definitive subtype assignment.

Slide 62 · Clinicopathologic application: Case 2

A child has coarse facial features, joint stiffness, and skeletal abnormalities. The family history suggests an X-linked trait, and corneal clouding is absent.

Which MPS syndrome should be prioritized, and what biochemical defect is expected?

Slide 63 · Case 2 interpretation

Hunter syndrome (MPS II) is supported by the X-linked inheritance pattern.

The deficient enzyme is iduronate 2-sulfatase.

Absent corneal clouding is a classic distinction from Hurler syndrome.

Clinical clues must be integrated with enzyme-based confirmation.

Slide 64 · Morphology application: Case 3

A tissue sample contains enlarged vacuolated connective-tissue cells. Stored granular material is PAS positive; Ultrastructure shows multiple swollen lysosomes.

What general mechanism best explains the vacuolated cells?

Slide 65 · Case 3 interpretation

Stored glycosaminoglycans cause lysosomal distension and cell enlargement.

Clear cytoplasm on light microscopy reflects lysosomal vacuoles.

Cellular appearance alone is not specific for a particular MPS subtype.

Interpret microscopy in the biochemical and clinical context.

Slide 66 · Mechanism application: Case 4

A patient with a glycosaminoglycan degradation disorder has short stature, malformed bones, joint stiffness, and chest-wall abnormalities.

Which cartilage compartments explain this combined skeletal pattern?

Slide 67 · Case 4 interpretation

Growth plates are implicated in impaired longitudinal growth.

Cartilage anlage abnormalities contribute to malformed bones.

Articular surfaces and costal cartilage help explain joint and chest-wall findings.

Chondrocyte injury and abnormal extracellular matrix unite the findings.

Slide 68 · Integrated clinicopathologic model

The molecular lesion is an inherited defect in lysosomal GAG degradation.

The tissue lesion is substrate storage, with chondrocyte apoptosis and matrix dysfunction.

The clinical phenotype couples skeletal malformation with visceral, cardiac, and sometimes CNS involvement.

Slide 69 · Core facts to retain

MPS is a multisystem lysosomal glycosaminoglycan storage disorder.

Cartilage injury explains short stature, skeletal deformities, and joint disease.

Balloon cells contain distended GAG-bearing lysosomes.

Hurler is α-L-iduronidase deficient; Hunter is iduronate 2-sulfatase deficient and X-linked.

Slide 70 · References

Principal textbook sources

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Chapter 26: Bones, Joints, and Soft Tissue Tumors. Printed p. 1070.

Robbins, Cotran & Kumar. Pathologic Basis of Disease. 11th ed. Chapter 5: Genes and Human Diseases. Printed pp. 139–140; Table 5.6.

Lecture schematics are original PowerPoint shapes, not clinical specimens or reproductions of textbook figures.